Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib as Initial Therapy for Accelerated Phase CML
NCT01570868Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2012; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01570868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01570868.